Programmable Bacteria Lysis Circuits for Localized Tumor Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including immunotherapy with checkpoint inhibitors, suffer from adverse effects and limited efficacy due to non-specificity and toxicity, while traditional methods like chemotherapy have significant side effects, and targeted therapies are limited to small subsets of patients.
Innovation Solution
Programmable bacteria engineered with synchronized lysis circuits and plasmids to deliver therapeutic agents such as nanobodies, toxins, tumor antigens, cytokines, and chemokines directly to tumors, providing controlled and localized delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are administered systemically to treat cancer, then tumor response is achieved, but immune-related adverse effects increase
Solution Approach 1:
The patent applies local quality by delivering checkpoint inhibitors specifically to the tumor site through bacteria that accumulate in tumors, rather than systemically. The bacteria target hypoxic regions of tumors and release therapeutic agents locally, achieving tumor response while minimizing immune-related adverse effects in other organs.
Solution Approach 2:
The patent uses bacteria as an intermediary delivery vehicle. The bacteria accumulate in tumors through hypoxia-induced mechanisms and serve as a mediator to transport checkpoint inhibitors from the injection site to the tumor interior, enabling localized delivery without systemic exposure.
2Object-affected harmful factors
If checkpoint inhibitors are delivered locally to tumors, then side effects are minimized, but delivery to difficult-to-reach hypoxic regions is limited
Solution Approach 1:
The bacteria perform self-service by autonomously accumulating in hypoxic tumor regions through their own hypoxia-induced mechanisms without external guidance. The bacteria self-target the difficult-to-reach areas where checkpoint inhibitors are most needed, overcoming delivery limitations.
Solution Approach 2:
The patent employs dynamic accumulation where bacteria actively migrate to and accumulate in hypoxic regions over time. The bacteria are not statically placed but dynamically accumulate in the most problematic tumor areas through their hypoxia-responsive behavior.
3Reliability
If traditional chemotherapy is used to treat cancer, then tumor shrinkage is achieved, but systemic toxicity increases
Solution Approach 1:
The patent applies local quality by confining the toxic therapeutic agents within bacteria that accumulate specifically in tumors. The bacteria release checkpoint inhibitors locally rather than distributing them systemically, achieving tumor shrinkage while avoiding the widespread tissue damage caused by traditional chemotherapy.
4Measurement precision
If targeted therapies are developed for specific cancer subtypes, then treatment precision is improved, but patient eligibility is limited
Solution Approach 1:
The patent applies universality by developing a bacterial delivery platform that can carry multiple different therapeutic agents (checkpoint inhibitors, cytokines, chemokines) and target multiple cancer types through hypoxia-induced accumulation. This single platform provides precise delivery for various cancer subtypes without requiring separate therapies for each.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The programmable bacteria effectively target tumors, minimizing side effects and enhancing therapeutic responses, including tumor shrinkage and immune activation, with reduced systemic toxicity.
Implementation Method 1
programmable bacteria comprising at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents
Implementation Method 2
These bacteria target and accumulate in difficult-to-reach areas of tumors, including hypoxic regions, through mechanisms induced by hypoxia
Data Source
AI summary
Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.